中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2014年
6期
119-121
,共3页
拉米夫定%失代偿期肝硬化%乙型肝炎
拉米伕定%失代償期肝硬化%乙型肝炎
랍미부정%실대상기간경화%을형간염
Lamivudine%Decompensated cirrhosis%Hepatitis B
目的：探讨拉米夫定联合合理营养规划治疗失代偿期乙型肝炎肝硬化疗效及预后情况。方法选取本院收治的96例失代偿期乙型肝炎肝硬化患者，随机分为观察组和对照组，对照组患者给予护肝等常规综合治疗，观察组患者在对照组基础上应用拉米夫定联合合理营养规划治疗，比较治疗后两组患者的肝功能情况和血清病理学指标，同时随访12、24、36个月，比较治疗后两组患者的病死率和肝癌发病率。结果两组患者治疗后肝功能指标、血清病毒学指标均有好转，观察组患者治疗后HBeAg转阴率（54.9%）和HBV-DNA转阴率（58.8%)）均高于对照组（P＜0.05）；观察组治疗后总胆红素（TBIL）、丙氨酸氨基转移酶（ALT）和Child-Pugh评分均低于对照组（P＜0.05）。随访12、24、36个月，观察组的病死率和肝癌发生率均明显低于对照组（P＜0.05）。结论拉米夫定联合合理营养规划治疗失代偿期乙型肝炎肝硬化，能有效改善患者的肝功能及其营养状况，降低肝癌发生率，延长患者生存期，效果显著。
目的：探討拉米伕定聯閤閤理營養規劃治療失代償期乙型肝炎肝硬化療效及預後情況。方法選取本院收治的96例失代償期乙型肝炎肝硬化患者，隨機分為觀察組和對照組，對照組患者給予護肝等常規綜閤治療，觀察組患者在對照組基礎上應用拉米伕定聯閤閤理營養規劃治療，比較治療後兩組患者的肝功能情況和血清病理學指標，同時隨訪12、24、36箇月，比較治療後兩組患者的病死率和肝癌髮病率。結果兩組患者治療後肝功能指標、血清病毒學指標均有好轉，觀察組患者治療後HBeAg轉陰率（54.9%）和HBV-DNA轉陰率（58.8%)）均高于對照組（P＜0.05）；觀察組治療後總膽紅素（TBIL）、丙氨痠氨基轉移酶（ALT）和Child-Pugh評分均低于對照組（P＜0.05）。隨訪12、24、36箇月，觀察組的病死率和肝癌髮生率均明顯低于對照組（P＜0.05）。結論拉米伕定聯閤閤理營養規劃治療失代償期乙型肝炎肝硬化，能有效改善患者的肝功能及其營養狀況，降低肝癌髮生率，延長患者生存期，效果顯著。
목적：탐토랍미부정연합합리영양규화치료실대상기을형간염간경화료효급예후정황。방법선취본원수치적96례실대상기을형간염간경화환자，수궤분위관찰조화대조조，대조조환자급여호간등상규종합치료，관찰조환자재대조조기출상응용랍미부정연합합리영양규화치료，비교치료후량조환자적간공능정황화혈청병이학지표，동시수방12、24、36개월，비교치료후량조환자적병사솔화간암발병솔。결과량조환자치료후간공능지표、혈청병독학지표균유호전，관찰조환자치료후HBeAg전음솔（54.9%）화HBV-DNA전음솔（58.8%)）균고우대조조（P＜0.05）；관찰조치료후총담홍소（TBIL）、병안산안기전이매（ALT）화Child-Pugh평분균저우대조조（P＜0.05）。수방12、24、36개월，관찰조적병사솔화간암발생솔균명현저우대조조（P＜0.05）。결론랍미부정연합합리영양규화치료실대상기을형간염간경화，능유효개선환자적간공능급기영양상황，강저간암발생솔，연장환자생존기，효과현저。
Objective To explore the clinical efifcacy on lamivudine treatment combination with reasonable nutrition plan for decompensated cirrhosis patients due to hepatitis B. Method 96 patients with decompensated cirrhosis in our hospital were included into this study. They were divided into the control group and the observation group. The observation group was treated with lamivudine and reasonable nutrition plan, the control group was treated with the comprehensive treatment. To sort and analyse the following variables:HBV-DNA level, ALT, ALB, TBIL and the rate of hepatocellular carcinoma, death rate at the 12, 24, 36 months. Result The liver function, serum virological indicators and after treatment were better than pre treatment in two group (P<0.05), the TBIL, ALT, Child-Pugh in control group was higher than that of observation group. The differences were signiifcant (P<0.05);the HBeAg and HBV-DNA negative in observation group was higher than that of control group. The differences were signiifcant (P<0.05);the rate of hepatocellular carcinoma, death rate at the 12, 24, 36 months in observation group was lower than that of control group. The differences were signiifcant (P<0.05). Conclusion Lamivudine treatment combination with reasonable nutrition plan for decompensated cirrhosis patients due to hepatitis B can effectively improve the clinical efifcacy and reduce the hepatocellular carcinoma and death rate.
